GREGORY MONTOYA: Open Payments
NPI 1083614176 · TEXARKANA, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,227 in 197 payments from 11 companies in 2025. Trend: 2023 $1,289 · 2024 $1,898 · 2025 $3,227
Food & beverage: $3,227
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 39 | $713 |
| Vanda Pharmaceuticals Inc. | 28 | $625 |
| Neurocrine BioSciences, Inc. | 24 | $519 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 31 | $394 |
| E.R. Squibb & Sons, L.L.C. | 16 | $290 |
| Alkermes, Inc. | 15 | $249 |
| ABBVIE INC. | 29 | $221 |
| Teva Pharmaceuticals USA, Inc. | 11 | $137 |
| Janssen Pharmaceuticals, Inc | 2 | $39 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $23 |
Products named: REXULTI, FANAPT, INGREZZA, CAPLYTA, COBENFY, ARISTADA, VRAYLAR, UZEDY.
Industry payments across TX — which companies pay providers there.
